Key Points
- ImmunityBio director Christobel Selecky sold 95,722 shares on June 29 at an average price of $9.01, totaling about $862,455.22. The sale reduced her ownership by 74.84% to 32,173 shares.
- The transaction was disclosed in an SEC filing and was executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates the sale was scheduled in advance.
- ImmunityBio recently reported quarterly results that missed earnings estimates but slightly beat revenue expectations. Analysts still broadly rate the stock a Moderate Buy, with an average target price of $14.20.
ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) Director Christobel Selecky sold 95,722 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $9.01, for a total transaction of $862,455.22. Following the transaction, the director owned 32,173 shares in the company, valued at $289,878.73. This trade represents a 74.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christobel Selecky also recently made the following trade(s):
- On Tuesday, June 30th, Christobel Selecky sold 1,000 shares of ImmunityBio stock. The stock was sold at an average price of $9.00, for a total transaction of $9,000.00.
ImmunityBio Stock Performance
IBRX opened at $9.20 on Thursday. The company has a market capitalization of $9.64 billion, a P/E ratio of -10.82 and a beta of 0.01. The company has a 50-day moving average of $7.65 and a 200-day moving average of $6.67. ImmunityBio, Inc. has a 1-year low of $1.95 and a 1-year high of $12.43.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The firm had revenue of $44.21 million for the quarter, compared to analyst estimates of $43.07 million. As a group, sell-side analysts expect that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. D. Boral Capital reiterated a "buy" rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of ImmunityBio in a research report on Tuesday, June 2nd. BTIG Research reaffirmed a "buy" rating and issued a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Piper Sandler reiterated an "overweight" rating and set a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of ImmunityBio in a report on Tuesday, April 14th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $14.20.
View Our Latest Stock Analysis on IBRX
Hedge Funds Weigh In On ImmunityBio
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Swiss Life Asset Management Ltd acquired a new stake in ImmunityBio in the 3rd quarter valued at approximately $27,000. WealthPlan Investment Management LLC acquired a new position in shares of ImmunityBio during the fourth quarter valued at $27,000. Diversify Advisory Services LLC bought a new stake in shares of ImmunityBio during the second quarter valued at about $27,000. Kovack Advisors Inc. acquired a new stake in ImmunityBio in the fourth quarter worth about $27,000. Finally, Cherry Creek Investment Advisors Inc. bought a new position in ImmunityBio in the 4th quarter valued at about $28,000. 8.58% of the stock is owned by institutional investors.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
